GlaxoSmithKline ((GSK)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
GlaxoSmithKline (GSK) has recently updated its clinical study assessing the efficacy of GSK3511294 (Depemokimab) compared to Mepolizumab or Benralizumab in treating severe asthma with an eosinophilic phenotype. Officially titled ‘A 52-week, Randomised, Double-blind, Double-dummy, Parallel Group, Multi-centre, Non-inferiority Study,’ the study aims to determine if switching to Depemokimab is as effective as maintaining current treatments in reducing asthma exacerbations. This study is significant as it could offer a new treatment option for severe asthma patients.
The study tests the biological intervention GSK3511294 (Depemokimab), administered via pre-filled syringes, against existing treatments Mepolizumab and Benralizumab. The goal is to establish Depemokimab’s non-inferiority in managing severe asthma symptoms.
Designed as a randomized, double-blind, parallel-group study, it involves participants continuing their standard asthma care while receiving either Depemokimab or the active comparators. The primary purpose is treatment-focused, ensuring unbiased results through double masking of participants and investigators.
Key dates for the study include its start on January 18, 2021, and the latest update on October 14, 2025. These dates are crucial as they mark the study’s progression and the availability of updated findings for stakeholders.
The study’s completion could influence GSK’s stock performance positively by potentially introducing a competitive asthma treatment to the market. This development might impact investor sentiment, especially as GSK positions itself against competitors in the respiratory treatment sector.
The study is ongoing, with further details available on the ClinicalTrials portal.